Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial
Min Yan(Dalian Institute of Chemical Physics), Fangzhou Xia(Jiangsu Hengrui Medicine (China)), Huimin Lv(Zhengzhou University), Huiai Zeng(Zhengzhou University), Xiaorui Li(Shandong University of Traditional Chinese Medicine), Fangyuan Dong(Liaoning Cancer Hospital & Institute), Limin Niu(Zhengzhou University), Zhichao Gao(Liaoning Cancer Hospital & Institute), Lingxiao Zhang(Sun Yat-sen University), Tao Sun(Liaoning Cancer Hospital & Institute), Huihui Sun(Zhengzhou University), Yuhua Song(Qingdao University), Zhenzhen Liu(Jilin University), Liping Liu(Lanzhou University), Li Li(Qilu Hospital of Shandong University), Jing Wang(Peking University), Yuting Chen(North Carolina State University), Jianghua Qiao(Henan Cancer Hospital), Guifang Zhang(Xinxiang Central Hospital), Danfeng Dong(First Affiliated Hospital of Xi'an Jiaotong University), Chunfang Hao(Tianjin Medical University Cancer Institute and Hospital), Zhanhong Chen(Cancer Hospital of Chinese Academy of Medical Sciences), Xiaohong Yang(Central South University), Mengwei Zhang(Zhengzhou University), Jin Yang(First Affiliated Hospital of Xi'an Jiaotong University), Yajing Feng(Zhengzhou University), Huawu Xiao(Central South University), Quchang Ouyang(Central South University), Xiuchun Chen(Henan Cancer Hospital)
Cited by 10
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
|The Lancet Respiratory Medicine|2018|477
Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers
|Proceedings of the National Academy of Sciences|2014|167
Trends in Hospitalization and In-Hospital Mortality From VTE, 2007 to 2016, in China
|CHEST Journal|2018|158
CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients
|Biomedicine & Pharmacotherapy|2015|126